The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine. A Multi-Center, Randomized, Double-Blind, Clinical Control Trial
Phase: PHASE3
Conditions: Headache
Sponsor: Mike O'Callaghan Military Hospital

Document Date: 2/21/2017 
NCT02735343 
 
The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine (Check) 

PROTOCOL FOR CLINICAL INVESTIGATION – NON-EXEMPT HUMAN 
(Wilford Hall Ambulatory Surgical Center – WHASC) 
PROTOCOL SUMMARY 
1.  Title: 
The CHECK Trial:  A Comparison of Headache Treatment in the Emergency Department:  Compazine versus Ketamine. A 
Randomized, Double-Blind, Clinical Control Trial. 
FWH20160057H 
 
2.0.  Principal Investigator (PI): 
 
                                                                WHASC PI: 
 
 
Name 
 
Christopher Pitotti, MD 
Rank/Corps or Civilian Rating 
 
Maj, USAF, MC 
Date of IRB Approved CITI Training & Date of Good Clinical Practice 
Training 
01/19/2016 
Branch of Service 
USAF 
AD Mil/DoD Civilian/Ctr/Non-DoD Civ 
AD Mil 
Department  & Base 
 
Department of Emergency Medicine, Nellis AFB 
Phone & Pager #  
(702) 653-3298 
E-Mail Address & AKO/DKO E-Mail Address 
christopher.pitotti.1@us.af.mil 
 
3.0. Research Plan:  
 
3.1. Purpose:   
This will be a prospective, double-blinded, randomized controlled trial on a convenience sample of patients presenting to the 
Emergency Department (ED) with a chief complaint of headache. 
 
3.2. Hypotheses, Research Questions or Objectives:  
We will determine the difference in pain scores between the compazine and Ketamine groups, as measured by a 25-mm 
difference between the groups mean on the visual analogue scale (VAS) at 60 min. 
 
4.  Brief Summary of the study:  
We are comparing Ketamine to compazine for benign headaches in the ED.  Subjects will be randomized into 1 of 2 groups.  
Group 1 will receive standard treatment of compazine 10 mg IV along with diphenhydramine (Benadryl) 25 mg IV. Group 2 (research 
arm) will receive Ketamine 0.3 mg/kg along with ondansetron (Zofran) 4 mg IV. Subjects will be seen at 15, 30, 45, and 60 minutes 
post-intervention to obtain Heart Rate, Blood Pressure, Headache severity, Nausea severity, Vomiting severity, Anxiety severity, and 
Restlessness severity. At 24-48 hours post intervention we will contact subjects and assess their pain and assess their satisfaction 
with their migraine pain management as part of this study. Subjects’ participation will last up to 48 hours post headache. 
Diphenhydramine (Benadryl) and Ondansetron (Zofran) are being given in this study to manage the side effects from the 
comparison medications (Compazine –akathisia, ketamine –nausea). Diphenhydramine (Benadryl) itself doesn’t add any benefit 
for migraines. [21] Ondansetron (Zofran) significantly reduces ketamine associated emesis [22]. Since nausea is common in 
migraines (73%) [23], and ketamine does not itself correct this it’s logical and ethical to add this as an adjunct for ketamine. If we 
didn’t add it to the regiment our satisfaction data would likely be clouded by persistent nausea. We are indeed comparing the 
two combinations but ondansetron (Zofran) and diphenhydramine (Benadryl) are simply adjuncts. 
    
5. Subjects:  
Male and female DoD beneficiaries aged 18-65 years who present to the Emergency Department (ED) with complaint of a 
headache will be recruited at the Mike O’Callaghan Federal Medical Center (MOFMC). No special populations (e.g., pregnant 
women, children, prisoners, detainees) will be recruited. 
 
6. Inclusion/exclusion criteria:  
Inclusion Criteria 
• 
Age 18 to 65 years who present to the ED with complaint of a headache 
• 
Temperature < 100.4° F 
• 
Diastolic blood pressure < 104 mm Hg 
• 
Normal neurologic exam and normal mental status 
Exclusion Criteria 
• 
Pregnant or breastfeeding 
• 
Meningeal signs are present 

• 
Acute angle closure glaucoma is suspected 
• 
Head trauma within the previous two weeks 
• 
Lumbar puncture within the previous two weeks  
• 
Thunderclap (rapid) onset of the headache 
• 
Weight more than 150 kg or less than 40 kg 
• 
Known allergy to diphenhydramine (Benadryl) 
• 
Known allergy to ondansetron. (Zofran) 
• 
Known allergy to compazine 
• 
Known allergy to Ketamine 
• 
History of schizophrenia or bipolar disorder 
• 
History of intracranial hypertension 
• 
Is a prisoner 
• 
Patient declined informed consent 
• 
Non-English speaking patient 
• 
Attending provider excludes patient 
• 
Elderly patients with dementia 
• 
Patients with severe headaches that diminish their decision making capability will not be able to participate. 
 
7.  Number of Subjects:   
TOTAL NUMBER OF SUBJECTS (nation-wide/study-wide):  70 
 
8.  Use of an Investigational New Drug:  
Ketamine and compazine are both drugs approved by the Food and Drug Administration. Ketamine is used as an analgesic 
during diagnostic and surgical procedures and compazine for the relief of nausea. In this protocol, they are both being used for 
a non-FDA approved indication (headache). Ketamine is frequently used for analgesia in the low doses described in this 
protocol.  We are not intending to change marketing, FDA approved indications, or change dosing requirements.  Compazine 
has been studied in multiple cases for migraine though is not specifically labeled for analgesia or migraine treatment, but is for 
nausea (an often experienced component of migraine). 
 
9.  Use of an Investigational Device:  N/A 
 
10. Use of a Placebo: N/A 

PROTOCOL FOR CLINICAL INVESTIGATION – NON-EXEMPT HUMAN 
(Wilford Hall Ambulatory Surgical Center – WHASC) 
1.  Title: 
The CHECK Trial:  A Comparison of Headache Treatment in the Emergency Department:  Compazine versus 
Ketamine. A Randomized, Double-Blind, Clinical Control Trial. 
FWH20160057H 
 
2.0.  Principal Investigator (PI): 
 
                                                                WHASC PI: 
 
Name 
 
Christopher Pitotti, MD 
Rank/Corps or Civilian Rating 
 
Maj, USAF, MC 
Date of IRB Approved CITI Training & Date of Good Clinical Practice 
Training 
01/19/2016 
Branch of Service 
USAF 
AD Mil/DoD Civilian/Ctr/Non-DoD Civ 
AD Mil 
Department  & Base 
 
Department of Emergency Medicine, Nellis AFB 
Phone & Pager #  
(702) 653-3298 
E-Mail Address & AKO/DKO E-Mail Address 
christopher.pitotti.1@us.af.mil 
 
2.1.  Associate Investigators (AI):   
Name 
AD/DoD Civ/Ctr/ 
Non-DoD Civ 
Rank/Corps or Civilian Rating/Title 
Date of CITI Training 
Phone & Pager #
Joseph Sontgerath, MD  
AD 
Capt, USAF, MC 
01/11/2016 
(702) 653-3298 
Lisa Mannina, MD 
AD 
Capt, USAF, MC 
11/09/2016 
(702) 653-3298 
 
2.2.  Research Assistants (RA) & Coordinators (RC):   
Name 
AD/DoD Civ/Ctr/ 
Non-DoD Civ 
Rank/Corps or Civilian Rating/Title 
Date of CITI Training 
Phone & Pager #
Jill Clark, MBA/HCM 
Ctr 
Senior Research Associate/Clinical 
Research Manager 
03/19/2014 
(702) 653-3298 
Tracy Bogdanovich, CCRC 
Ctr 
Clinical Research Coordinator 
03/31/2014 
(702) 653-2088 
Lisa Stammers, RN, BSN 
DoD Civ 
DME Nurse 
06/17/2014 
(702) 653-3239 
Daniel Shaffer, BSBA 
Ctr 
Clinical Research Coordinator 
06/29/2015 
(702) 653-2067 
Heather Rider, B.S. 
Ctr 
Clinical Research Coordinator 
07/15/2015 
(702) 653-2521 
Jennie Moss, RN, M.S. 
CTR 
Senior Research Associate 
09/01/2015 
(702) 653-3644 
Amanda Crawford, B.A. 
CTR 
Clinical Research Coordinator 
09/27/2016 
(702) 653-2113 
 
2.3.  The research relevance of this protocol focuses on: [x] Treatment 
 
2.4.  Location(s):   
a.  Collaborating Facilities: N/A 
 
b.  Air Force Sites seeking Regional IRB: Mike O’Callaghan Federal Medical Center, Jill Clark, (702) 653-
3298 
 
c.  List study sponsors: N/A 
 
3.  Research Plan:  
 
3.1. Purpose:   
This will be a prospective, double-blinded, randomized controlled trial on a convenience sample of patients 
presenting to the Emergency Department (ED) with a chief complaint of headache. 
 
3.2. Hypotheses, Research Questions or Objectives:  

We will determine the difference in pain scores between the compazine and Ketamine groups, as measured by 
a 25-mm difference between the groups mean on the visual analogue scale (VAS) at 60 min. 
 
3.3.  Significance:   
Approximately 2.8% of ED visits are related to headache with a large percentage due to migraines making this 
diagnosis and its management a daily challenge for EM physicians [1].  The range of medications used to treat 
migraines has expanded without a clear first line therapy and each class has its own limitations not limited to 
medication interactions, cardiac effects, and short administration windows.  Finding a safe and effective 
alternative to standard therapy could potentially save costs, reduce repeat visits, and more importantly 
alleviate this common and painful condition. 
 
3.4.  Military Relevance:   
Military Treatment Facilities often treat this condition. Low Dose Ketamine (LDK) has been extensively studied 
for battlefield analgesia and thus is often available to the downrange provider whereas phenothiazines such as 
compazine or alternative migraine treatments may not be. There is the potential for returning patients to 
function earlier, improving readiness and reducing the reliance on quarters for this condition’s management.  
  
3.5.  Background and Review of Literature: 
In the emergency department (ED), one of the most common chief complaints is headache [1].   A number of 
prior studies have demonstrated the efficacy of a variety of medications for migraines and other benign 
headaches [2].  Some of the options for treating these types of headaches include dopamine antagonists, 
opioids, non-steroid anti-inflammatory drugs (NSAIDs), triptans, anti-epileptics, and ergot derivatives [2].  
Amongst the available options, dopamine antagonists appear to be the most effective, with multiple studies 
demonstrating their superiority over opioids [3], NSAIDs [4], triptans [5], and anti-epileptics [6].  The dopamine 
antagonist that we use most frequently, and the one that has the most evidence to support its use for benign 
headaches, is compazine [5,6,7,8,9,10].  Although some data suggest that droperidol may be even more 
effective than compazine [11], the current national shortage limits its use.     
 
Despite the general effectiveness of dopamine antagonists and the variety of options for benign headache 
treatment, many patients who present to the ED still have headaches 24 hours after treatment.  In one study 
by Friedman, 31% of patients still had moderate to severe headaches 24 hours after discharge [12].  Often we 
resort to opiates in refractory headaches despite evidence to suggest that opiates increase both length of stay 
and bounce backs [13]. 
 
Ketamine is an N-Methyl-D-aspartate (NMDA) receptor antagonist that has both analgesic and dissociative 
properties [14].  Previous studies have demonstrated the effectiveness of Ketamine for post-operative pain 
[15,16], pain in burn patients [17], and chronic pain [18].  New studies have also shown Ketamine to be useful 
for acute pain in the ED by both the intranasal [19] and intravenous routes [20].  To our knowledge, there are 
no prospective studies that evaluate the effectiveness of Ketamine for the treatment of benign headaches in 
the ED.    
 
Diphenhydramine (Benadryl) and Ondansetron are being given in this study to manage the side effects from 
the comparison medications (Compazine –akathisia, ketamine –nausea). Diphenhydramine (Benadryl) itself 
doesn’t add any benefit for migraines. [21] Ondansetron (Zofran) significantly reduces ketamine associated 
emesis [22]. Since nausea is common in migraines (73%) [23], and ketamine does not itself correct this it’s 
logical and ethical to add this as an adjunct for ketamine. If we didn’t add it to the regiment our satisfaction 
data would likely be clouded by persistent nausea. We are indeed comparing the two combinations but 
ondansetron (Zofran) and diphenhydramine (Benadryl) are simply adjuncts. 
 
3.5.1. Bibliography:  
1. Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 emergency 
department summary. National health statistics reports; no 7. Hyattsville, MD: National Center for Health 
Statistics. 2008. 

2. Gelfand AA, Peter J. Goadsby PJ.  A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room.  
The Neurohospitalist 2012 2: 51 
3. Cicek M, Karcioglu O, Parlak I, et al. Prospective, randomised, double blind, controlled comparison of 
metoclopramide and pethidine in the emergency treatment of acute primary vascular and tension type 
headache episodes. Emerg Med J. 2004;21:323-326. 
4. Friedman BW, Adewunmi V, Campbell C, et al.  A Randomized Trial of Intravenous Ketorolac Versus 
Intravenous Metoclopramide Plus Diphenhydramine for Tension-Type and All Nonmigraine, Noncluster 
Recurrent Headaches.  Annals of Emergency Medicine.  2013:62(4):311-318. 
5. Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT.  A Prospective, Randomized Trial of Intravenous 
Prochlorperazine Versus Subcutaneous Sumatriptan in Acute Migraine Therapy in the Emergency 
Department.  Annals of Emergency Medicine.  2009. 
6. Tanen DA, Miller S, French T, Riffenburgh RH.  Intravenous Sodium Valproate Versus Prochlorperazine for 
the Emergency Department Treatment of Acute Migraine Headaches: A Prospective, Randomized, Double-
Blind Trial.  Ann Emerg Med. 2003;41:847-853. 
7. Jones J, et al. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute 
headache. JAMA.1989;261:1174-1176. 
8. Friedman BW, Esses D, Solorzano C, et al.  A Randomized Controlled Trial of Prochlorperazine Versus 
Metoclopramide for Treatment of Acute Migraine.  Annals of Emergency Medicine 2008: 52(4): 399-406. 
9. Callan JE, Kostic MA, Bachrach EA, Rieg TS.  Prochlorperazine versus Promethazine for Headache Treatment 
in the Emergency Department:  A Randomized Controlled Trial.  J Emerg Med. 2008; 35:247-253. 
10. Coppola M, Yealy DM, Leibold RA.  Randomized, Placebo-Controlled Evaluation of Prochlorperazine Versus 
Metoclopramide for Emergency Department Treatment of Migraine Headache.  Annals of Emergency 
Medicine 1995. 
11. Miner JR, et al. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad 
Emerg Med. 2001;8:873-879. 
12. Friedman BW, Hochberg ML, Esses D, et al.  Recurrence of primary headache disorders after Emergency 
Department discharge:  frequency and predictors of poor pain and functional outcomes.  Ann Emerg Med.  
2008 Dec:52(6):696-704. 
13. McCarthy LH, Cowan RP.  Comparison of parenteral treatments of acute primary headache in a  large 
academic emergency department cohort.  Cephalalgia.  2015 Aug;35(9):807-15. 
14. Adams HA.  Mechanisms of action of Ketamine.  Anaesthesiol Reanim.  1998;23(3):60-3. 
15. Eghball MH, Taregh S, Amin A, Sahmeddini MA.  Ketamine Improves Postoperative Pain and Emergence 
Agitation Following Adenotonsillectomy in Children:  A Randomized Clinical Trial.  M.E.J. ANESTH 22 (2), 
2013. 
16. Weinbroum AA. A single small dose of postoperative Ketamine provides rapid and sustained improvement 
in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg 2003;96:789–795. 
17. McGuinness SK, Wasiak J, Cleland H, et al. A systematic review of Ketamine as an analgesic agent in adult 
burn injuries. Pain Med 2011;12:1551–1558. 
18. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 
2003;97:1730–1739. 
19. Andolfatto G, Willman E, Joo D, et al.  Intranasal Ketamine for Analgesia in the Emergency Department: A 
Prospective Observational Series.  Acad Emerg Med.  2013;20(10):1050-1054. 
20. Motov S, Rockoff B, Cohen V, et al.  Intravenous Subdissociative-Dose Ketamine Versus Morphine for 
Analgesia in the Emergency Department: A Randomized Controlled Trial.  Ann of Emerg Med.  
2015;66(3):222-229. 
21. Friedman B, Cabral L, Adewunmi V, et al. Diphenhydramine as Adjuvant Therapy for Acute Migraine: 
An Emergency Department-Based Randomized Clinical Trial. Ann Emerg Med. 2016 Jan;67(1):32-39.e3. 
22. Langston W, Wathen J, Roback M, Bajaj L. Effect of Ondansetron on the Incidene of Vomiting Associated 
with Ketamine Sedation in Children: A Double-Blind, Randomized, Placebo-Controlled Trial. Ann of Emerg 
Med. 2008 (1) 326. 
23. Lipton R, Stewart W, Diamond S, et al. Prevalence and burden of migraine in the United States: data from 
the American Migraine Study II. Headache. 2001 Jul-Aug;41(7):646-57. 
24. Callan J, Kostic M, Bachrach E, et al. Proclorperazine vs. promethazine for headache treatment in the 

emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct: 35(3):247-53. 
25. Tanen D, Miler S, French T, et al. Intravenous sodium valproate versus prochlorperazine for the emergency 
department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann 
Emerg Med. 2003 Jun:41(6):847-53. 
26. Coppola M, Yealy D, Leibold R. Randomized, placebo-controlled evaluation of prochlorperazine versus 
metoclopramide for emergemcy department treatment of migraine headache. Ann Emerg Med. 1995. 26(5): 
541-546. 
27. Jones J, Pack S, Chun E. Intramuscluar prochlorperazine versus metoclopramide as single-agent therapy for 
the treatment of acute migraine headache. Am J Emerg Med. 1996. May: 14(3): 262-4. 
 
3.6.  Research Design and Methods:  
Male and female DoD beneficiaries aged 18-65 years who present to the ED with complaint of a headache will 
be offered an opportunity to participate in the study at the Mike O’Callaghan Federal Medical Center (MOFMC). 
Research subjects will be recruited when both research staff and a trained Pharmacist attached to this study are 
available. The PI or AI will not recruit their own patients to prevent any misconception of coercion or undue 
influence. 
 
Screening Visit: 
• 
Obtain signed Informed Consent Document and HIPAA Authorization (research-driven). 
• 
Record: Date of birth, age, phone number, gender, race, ethnicity, social security number, name of 
standard of care rescue medications (over-the-counter and prescription), current email address (to be 
used for scheduling only), height (in inches), weight (in pounds), history of traumatic brain injury, 
concussion, or any mild to severe head trauma, medication use. (research only) 
• 
Review past medical history in Armed Forces Health Longitudinal Technology Application (AHLTA) or 
ESSENTRIS to verify the inclusion/exclusion criteria. 
• 
Women of childbearing potential will have a serum pregnancy test (5-10 milliliters, approximately 1-2 teaspoons 
of blood) or urine pregnancy test (10 drops or less than 1 milliliter of urine)  (research-driven). 
 
Visit 1: 
• 
Heart rate 
• 
Blood pressure 
• 
Headache severity via 100-mm VAS. 
• 
Nausea severity via 100-mm VAS. 
• 
Vomiting severity via 100-mm VAS. 
• 
Anxiety severity via 100-mm VAS. 
• 
Restlessness severity via 100-mm VAS. 
• 
Record type and amount of rescue medications (over-the-counter and prescription) use in the past 7 days. 
(research only) 
• 
Subjects will be randomized by the pharmacy.  We will use a random-number generator and use blocking 
to ensure roughly equal sample sizes.  Both subjects and investigators will be blinded to the study group 
assignments.  Subjects will be randomized by the pharmacy into one of two groups (research-driven): 
o 
Group 1: Standard treatment arm (compazine 10 mg IV along with diphenhydramine(Benadryl) 25 mg 
IV) 
o 
Group 2: Research arm (Ketamine 0.3 mg/kg along with ondansetron (Zofran) 4 mg IV) 
 
15 minutes post treatment: 
• 
Heart rate 
• 
Blood pressure 
• 
Headache severity via 100-mm VAS. 
• 
Nausea severity via 100-mm VAS. 
• 
Vomiting severity via 100-mm VAS. 
• 
Anxiety severity via 100-mm VAS. 

• 
Restlessness severity via 100-mm VAS. 
 
30 minutes post treatment: 
• 
Heart rate 
• 
Blood pressure 
• 
Headache severity via 100-mm VAS. 
• 
Nausea severity via 100-mm VAS. 
• 
Vomiting severity via 100-mm VAS. 
• 
Anxiety severity via 100-mm VAS. 
• 
Restlessness severity via 100-mm VAS. 
 
45 minutes post treatment: 
• 
Heart rate 
• 
Blood pressure 
• 
Headache severity via 100-mm VAS. 
• 
Nausea severity via 100-mm VAS. 
• 
Vomiting severity via 100-mm VAS. 
• 
Anxiety severity via 100-mm VAS. 
• 
Restlessness severity via 100-mm VAS. 
 
60 minutes post treatment: 
• 
Heart rate 
• 
Blood pressure 
• 
Headache severity via 100-mm VAS. 
• 
Nausea severity via 100-mm VAS. 
• 
Vomiting severity via 100-mm VAS. 
• 
Anxiety severity via 100-mm VAS. 
• 
Restlessness severity via 100-mm VAS. 
 
24-48 hours post treatment: 
• 
Subjects will be contacted either in-person or via phone and the following information will be collected: 
o 
Subjects will be asked “On a scale of 0-10, with 10 being the worst pain, what is your current level of 
pain?” 
o 
Subjects will be asked “On a scale of 0 to 10, how satisfied were you with your migraine pain management 
as part of this research study? (dissatisfied 0 – 10 very satisfied) 
• 
Subjects will be alerted to what group they were randomized into. 
 
Dose Administration: The diphenhydramine (Benadryl) or ondansetron (Zofran) will be administered first, and 
immediately afterward the compazine or Ketamine will be administered. For prevention/treatment of 
akisthesia from Compazine, diphenhydramine (Benadryl) is standard of care. For treatment of nausea, ketamine 
or otherwise ondansetron (Zofran) is a standard of care drug, other medications are often used with 
equivalent effectiveness but overlap class with the study drug Compazine in their use for migraines so would 
interfere with interpreting results. Ondansetron (Zofran) is not commonly used as an abortive for migraines. 
The compazine or Ketamine will be diluted in saline so that the total volume is 3 mL, and will be administered 
over 2 minutes.  The diphenhydramine (Benadryl) will be diluted in saline so that it is 2 mL (the same volume as 
the ondansetron (Zofran)).  Both groups will also receive a 500 mL normal saline bolus after the study 
medications are administered.  The hospital pharmacist will be responsible for preparing the medications, using 
a double-blind protocol, and record which arm the patient was randomized to.   Only the pharmacist and the 
Research Coordinator will have access to the randomization records and will not reveal the randomization until 
the end of the study.  Emergency providers will be instructed not to administer any rescue medications for at 
least 30 minutes.  The electronic medical record order will read “randomized study medication” (for the 

Ketamine or compazine) and “randomized add-on medication” (for the ondansetron (Zofran) or 
diphenhydramine (Benadryl)). It is common practice to use the combination of compazine and 
diphenhydramine (Benadryl) or ketamine and ondansetron (Zofran). If the patient receives a rescue 
medication, he or she will definitely NOT be withdrawn from the study.  The need for rescue medication is a 
secondary outcome of the study.  We will still analyze groups based upon their original randomization and the 
intention to treat principle.  Rescue medications do not bias the study results, and they have been part of every 
headache treatment study I have ever read. The data from the first 30-minutes will be maintained as research 
data, and this is important data for the study. 
 
Safety: After 30 minutes, the treating provider will be permitted to administer any medication they would like 
for further treatment.  Only if there is an untoward event that requires the treating provider to know which 
medication was administered will the pharmacist unblind the randomization for that individual patient. 
 
3.6.1. Interventions, Observations, or Data Sought:  
The primary outcome measure will be the difference in pain scores between the compazine and Ketamine 
groups, measured as the absolute difference between the means at 60 min.  Secondarily, we will measure the 
difference between the rates of decline in pain scores, rate of admission, nausea scores, rate of vomiting, rate 
of development of akathisia, heart rate and blood pressure changes, headache resolution with telephone 
follow up, and patient satisfaction. 
 
3.6.2. Data Collection and Processing:  
Data will be collected and recorded in a spreadsheet. At the conclusion of the study, all personally identifying 
information will be removed prior to analysis. De-identified data will be shared with research staff at University 
Medical Center of Southern Nevada at the conclusion of the study. A Cooperative Research and Development 
Agreement (CRADA) for the data sharing is pending. 
 
3.6.3. Setting:  
Male and female DoD beneficiaries aged 18-65 years will be recruited at the Mike O’Callaghan Federal Medical 
Center (MOFMC). No special populations (e.g., pregnant women, children, military basic trainees, prisoners, 
detainees) will be recruited. 
 
3.6.4. Date(s):  
April 2016-April 2019 
 
3.6.5. Source of Research Material: 
Source of Research Material per Participant 
(Procedures) 
# Routine 
Care 
# Research 
Driven 
# Total 
Procedures 
Medical Record Review 
0 
1 
1 
Serum or urine pregnancy test 
0 
1 
1 
Heart rate 
0 
5 
5 
Blood pressure 
0 
5 
5 
Headache severity via 100-mm VAS 
0 
5 
5 
Nausea severity via 100-mm VAS 
0 
5 
5 
Vomiting severity via 100-mm VAS 
0 
5 
5 
Anxiety severity via 100-mm VAS 
0 
5 
5 
Restlessness severity via 100-mm VAS 
0 
5 
5 
 
3.6.6. Subjects:  
Male and female DoD beneficiaries aged 18-65 years who present to the ED with complaint of a headache will 
be recruited at the Mike O’Callaghan Federal Medical Center (MOFMC). No special populations (e.g., pregnant 
women, children, prisoners, detainees) will be recruited. 
 

3.6.7. Inclusion/Exclusion Criteria:  
Inclusion Criteria 
• 
Age 18 to 65 years who present to the ED with complaint of a headache 
• 
Temperature < 100.4° F 
• 
Diastolic blood pressure < 104 mm Hg 
• 
Normal neurologic exam and normal mental status 
 
Exclusion Criteria 
• 
Pregnant or breastfeeding 
• 
Meningeal signs are present 
• 
Acute angle closure glaucoma is suspected 
• 
Head trauma within the previous two weeks 
• 
Lumbar puncture within the previous two weeks  
• 
Thunderclap (rapid) onset of the headache 
• 
Weight more than 150 kg or less than 40 kg 
• 
Known allergy to diphenhydramine (Benadryl) 
• 
Known allergy to ondansetron. (Zofran) 
• 
Known allergy to compazine 
• 
Known allergy to Ketamine 
• 
History of schizophrenia or bipolar disorder 
• 
History of intracranial hypertension 
• 
Is a prisoner 
• 
Patient declined informed consent 
• 
Non-English speaking patient 
• 
Attending provider excludes patient 
• 
Elderly patients with dementia 
• 
Patients with severe headaches that diminish their decision making capability will not be able to 
participate. 
 
3.6.8. Instrumentation: N/A 
 
4.0.  Human Subject Protection:  
 
4.1. Recruitment:  
All potentially eligible patients, presenting to the ED with a chief complaint of headache, will be offered an 
opportunity to participate. Some patients may be patients of the PI or AI, however, they will have the study 
staff recruit their patients to prevent any misconception of coercion or undue influence. When a potential 
subject is identified by the treating physician, the Research Staff will be contacted to speak with the patient 
directly. Research subjects will be recruited when both research staff and a trained Pharmacist attached to this 
study are available. Research subjects will be offered the opportunity to participate when they present to the 
Emergency Department either when they check-in, are waiting in the waiting area, or being triaged by Emergency 
Department personnel. Emergency Department staff will ask the patient if they are willing to speak with the 
research staff and, if they agree, then the research staff will be contacted to come discuss the study with the 
potential participant. An advertisement will be placed in the Emergency Department. 
 
4.2. Consent Processes:  
Informed Consent and HIPAA authorization will be sought in advance of any study-related procedures from 
each prospective subject and appropriately documented in accordance with 32 CFR 219.117. Potential 
candidates will be notified about the study either through posted advertisements or by their care provider and 
will be given the opportunity to consent by one of the referred study coordinators. The study coordinator will 
provide a written copy of the Informed Consent Document (ICD). The subject may decline to consent without 
prejudice. At the subjects’ discretion, they may take the ICD home to discuss further prior to making a decision 

and if they decide they are interested in participating, they can contact the research department the next time 
they present to the Emergency Department with a headache. If the subject consents, a copy of the ICD will be 
given to the subject. No vulnerable populations are included in this research study. Subjects who cannot 
provide Informed Consent will not be allowed to participate. No Legally Authorized Representatives (LAR) will 
be utilized. Patients who experience severe headaches that are unable to provide informed consent will not be 
able to participate. 
 
4.3 Participation Compensation:  
Subjects will not be paid for participation in this study. 
 
4.4. Assent Process: N/A 
 
4.5. Benefits:  
There may be no direct benefits to the subjects for participating in this study.  Personal benefits include 
intended reduction in headache symptoms and the satisfaction that the patient may be assisting investigators 
in determining a more effective headache treatment. 
 
4.6. Risks: There is a risk of inadvertent breach of confidentiality. The potential risks to participate in this study 
are minimal and include: 
DRUG NAME 
LIKELY and not 
serious 
LESS LIKELY and not serious 
RARE and serious 
COMPAZINE 
(PROCHLORPERAZINE) 
Drowsiness 
Blurred vision 
Xerostomia (dry mouth) 
Congestion 
Nausea 
Akasthisia (restlessness) 
Tardive dyskinesia (involuntary 
movements) 
Electrocardiogram (ECG) changes 
Tachycardia (rapid heartbeat) 
Constipation 
Urinary retention 
Allergic reaction 
Neuroleptic Malignant 
Syndrome (NMS) 
Blood dyscrasia (disease) 
Hypotension (low blood 
pressure) 
 
KETAMINE 
Drowsiness 
Sialorrhea (excessive drooling) 
Nausea/vomiting 
Elevation in blood pressure or 
heart rate 
Nystagmus/diplopia (uncontrolled 
eye movements) 
Fasciculations (muscle twitch) 
Hallucinations 
Bradycardia (slow heart rate) 
Hypotension (Low blood 
pressure) 
Arrythmias (abnormal heart 
rhythm) 
Respiratory depression 
Cystitis (bladder inflammation) 
Pain at injection site 
None 
ONDANSETRON 
(ZOFRAN) 
None 
Headache 
Constipation 
Diarrhea 
Serotonin syndrome 
Torsade de pointes 

Dizziness 
Drowsiness 
Fatigue 
Weakness 
QT interval prolongation 
Abdominal pain 
Dry mouth 
Elevated liver enzymes 
Stevens-Johnson 
Syndrome 
Toxic Epidermal 
Necrolysis 
Hypersensitivity 
ECG changes 
DIPHENHYDRAMINE 
(BENADRYL) 
Drowsiness 
Dry mouth 
Dizziness 
Headache 
Blurred vision 
Tinnitus 
Hypotension 
Palpitations 
Anorexia 
Dry mouth 
Constipation 
Nausea 
Dysuria (Painful or difficult 
urination) 
Urinary retention or increase in 
frequency 
None 
 
4.7. Costs: N/A 
 
4.8. Safeguards for Protecting Information:   
The research consents will be stored in a locked cabinet in a locked room.  Medical records will be annotated 
with ICD-10 code Z00.6 to reflect the subject’s participation in a research study. All research data including 
patient demographics will be kept in an electronic database, which will be encrypted, double password 
protected and the access will be restricted.  The research data will be coded and any links to identifiable data 
will be destroyed as soon as the Final Report Approval has been obtained from the IRB. Only the pharmacist 
and the Research Coordinator will have access to the randomization records and will not reveal the 
randomization until the end of the study or in the event of a research related adverse event. The anonymized 
research data will not be utilized for further research activity beyond the protocol stipulations without 
additional IRB approval. De-identified data will be shared with research staff at the University Medical Center 
of Southern Nevada at the conclusion of the study. A Cooperative Research and Development Agreement 
(CRADA) for the data sharing is pending. 
 
4.9. Safeguards for Protecting Subjects:  
The principal investigator will be responsible for the protocol safety monitoring.  The PI will make study 
documents (e.g., consent forms, data pulls) and pertinent hospital or clinical records readily available for 
inspection by the local IRB and oversight staff for confirmation of the study data. 
 
4.9.1. Minimizing Risks:   
Subjects will have access to study personnel should they have any issues.  If there are any issues, they will be 
immediately reported to one of the Investigators and an applicable medical evaluation will be initiated. 
 
4.9.2. Vulnerable Populations: N/A 
 
4.9.3. Clinical Care:  

All subjects will receive standard of care regardless of inclusion into this study. If at any time a subject 
experiences any injury or adverse effects, appropriate clinical care will be given or subject will be referred to 
appropriate provider. 
 
4.9.4. Injury Compensation: N/A 
 
4.9.5. Data Safety Monitoring:  
The principal investigator will be responsible for the protocol safety monitoring.  The PI will make study 
documents (e.g., consent forms, data pulls) and pertinent hospital or clinical records readily available for 
inspection by the local IRB and over sight staff for confirmation of the study data. 
 
5.0. Alternatives:  
The alternative is to receive standard of care and not to participate in this study. 
 
6.0. Data Analysis:  
A couple prior studies have used a 25-mm difference in mean VAS score reduction between groups to show a 
clinical benefit [6,9].  We define adequate pain relief as an absolute decrease in the mean VAS score of 25 mm 
[24, 25, 26, 27].   
 
6.1. Outcome Measures:  
The primary outcome measure will be the difference in pain scores between the compazine and Ketamine 
groups, measured as the absolute difference between the means at 60 min.  Secondarily, we will measure the 
difference between the rates of decline in pain scores, rate of admission, nausea scores, rate of vomiting, rate 
of development of akathisia, heart rate and blood pressure changes, headache resolution with telephone 
follow up, and patient satisfaction. 
 
6.2. Sample size estimation/power analysis:   
Thirty-two patients will be needed in each group to find a 25-mm difference between the group means on the 
VAS at 60 min, with a power of 0.80 and an alpha of 0.05.  We will aim for 35 patients per group to account for 
about a 10% dropout rate 
 
6.3. Statistical Analysis:  
The groups will be compared using a t -test on gender, race, and age; and a χ2 test with Yates correction on 
severity of presenting headache, to determine if they are similar.  The individual VAS measurements will be 
compared using a repeated measures analysis of variance (ANOVA) test. 
 
6.4 Number of Subjects:   
Number of subjects planned for 
MOFMC 
Enrolled in 
Study   
70 
to result 
in 
64 
completing the 
study. 
TOTAL NUMBER OF SUBJECTS (nation-wide/study-wide): 70 
 
7. Duration of Study: Approximate duration of the study: 3 year 
8.  Local and External Support Services:  Pharmacy Letter of Support 
9.  Intramural (GME) and Extramural Funding Support:  None 
10. Conflict of Interest: None 
 
11.  Use of an Investigational New Drug, use of a Drug for a non-FDA approved purpose, use of an investigative 
device or use of a placebo:   
This research uses an Investigational New Drug 
 
 
 
 
 
[] YES 
[x] NO 
This research uses a FDA approved drug for a non-FDA approved purpose                                                                          
[x] YES 
[] NO 

This research uses an Investigational Device       
 
 
 
 
 
[] YES 
[x] NO 
This research uses a placebo. 
 
 
                                                                                   
 
[] YES 
[x] NO 
 
12.  Medical Research Area for the Study:  (Pick as many as appropriate) 
[] Analytical Chemistry 
[] Anatomy 
[] Anesthesiology 
[] Biochemistry 
[] Cardiovascular 
Surgery 
[] Cardiology 
[] Cell Biology 
[] Dentistry 
[] Dermatology 
[] Dietetics 
[] Electrophysiology 
[] Endocrinology 
[x] Emergency 
medicine 
[] Gastroenterology 
[] General Surgery 
[] Hematology 
[] Histology 
[] Immunology/Allergy 
[] Infectious Disease 
[] Microbiology 
[] Molecular Biology 
[] Neonatology 
[x] Neurology 
[] Neurosurgery 
[] Nursing 
[] OB/GYN 
[] Occupational Medicine 
[] Occupational Therapy 
[] Oncology 
[] Ophthalmology 
[] Oral/Maxillofacial 
Surgery 
[] Orthopedics 
[] Pathology 
[] Pediatrics 
[] Pharmacology 
[] Physical Therapy 
[] Mental Health 
[] Radiology/Imaging 
[] Urology 
[] Wellness 
[] Other (state): 
 
 
13. Attachments:  
1. 
Form A-Signature Sheet 
2. 
Form A2-Study Personnel 
3. Advertisement 
4. Certificate of Compliance 
5. Informed Consent Document 
6. HIPAA Authorization Document 
7. Form O: Use of a Drug in Research 
8. Pharmacy Support Letter